Evaluation of Treatment Predictors Reflecting Beta-catenin Activation in Hepatocellular Carcinoma

Eligibility Criteria

• * Age 18 years or older (no upper limit of age)
• * Hepatocellular carcinoma diagnosis made histologically or radiographically in accordance to National Comprehensive Cancer Network guidelines (3.2019 version or higher)
• * Does not qualify for surgical resection or locoregional therapy alone or has disease that has progressed after surgical resection and/or locoregional therapy
• * Has measurable disease defined as at least one tumor lesion that can be accurately measured according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 on CT/MRI completed within past 6 weeks of eligibility screening
• * Under the care of a licensed medical oncologist
• * Life expectancy \> 6 months
• * Deemed eligible for treatment with an immune checkpoint inhibitor agent based on the treating medical oncologist's assessment of previous treatment failure, clinical/performance/virology status, and liver/renal/hematologic function.
• * Child-Pugh score of 9 or less
• * Creatinine clearance ≥ 40 mL/min, measured or calculated using the Cockcroft-Gault formula
• * ALT and AST ≤7x upper limit of normal
• * Total bilirubin ≤4 mg/dL
• * Albumin ≥2.8 g/dL
• * Weight \> 500 lbs (PET/CT limit)
• * Pregnant or lactating female (those of child-bearing potential must be re-screened within 7 days prior to PET/CT imaging)
• * Serious underlying medical condition that would impair patient's ability to tolerate the imaging procedure
• * Concurrent treatment with a non-targeted therapeutic agent. Concurrent enrollment in an ICI-treatment trial and combination ICI treatment are allowed.